Rocket Lab Corporation

How Investing Has Changed in the Last 5 Years

Key Points
Rigetti Computing, Rocket Lab, and Robinhood Markets have been some of the hottest growth stocks to own over the past year.
All three have tremendous growth prospects, but only one has profits.
Investing in hot growth stocks can produce life-changing gains, even over relatively short time frames. Those potential profits are what make taking on greater levels of risk in the market a worthwhile endeavor. Still, you don't want to overdo the risk by putting too much of your portfolio into a single asset. So, for example, rather than investing $10,000 into one growth stock, you might consider putting $2,000 into five different companies. True, that type of diversification will reduce your exposure to your biggest winners, but it also cushions your portfolio from the impact of any underperformers.
Even a $2,000 investment can prove to be seriously rewarding when you're talking about growth stocks. Three excellent examples are Rigetti Computing (NASDAQ: RGTI), Rocket Lab (NASDAQ: RKLB), and Robinhood Markets (NASDAQ: HOOD). If you invested $2,000 into each of these stocks on Halloween last year, the combined value of those positions would now (as of Oct. 17) be around $91,000. Here's how much a $2,000 investment in each of those stocks made just under a year ago would be worth today, and why they have rallied so much.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
Rigetti Computing: $66,000
Investing in Rigetti Computing a year ago would have required a willingness to take on considerable risk. The business was not profitable then, and it still isn't. Investors have mainly bid the shares up based on the expectation that it will be a leading quantum computing company in the future. It could take more than a decade before there are any clear winners in the quantum computing market, but in the meantime, Rigetti has been among the hottest stocks to own in 2025.
Since last Halloween, the tech stock has soared 3,200%, and a $2,000 investment would now be worth around $66,000. That phenomenal return would have been next to impossible to predict back then. This again highlights the risks and opportunities of investing in these small growth stocks: It can be difficult to predict which direction they might go.
As well as Rigetti has done in the past year, however, it could make for a scary stock to be holding today, just because its valuation has gotten so rich. The business only generates around $2 million in sales per quarter. With its current market cap of $14 billion, that gives it a bloated price-to-sales ratio in excess of 1,100.
There's a lot of downside risk to this stock, as the company still has a long way to go in proving that it's the real deal. While Rigetti looks unstoppable today, back in 2023 when quantum computing wasn't so hot, it was a much different story. In May 2023, Rigetti's stock would plummet to a low of just 38 cents -- falling by 95% over a one-year period.
This is a highly volatile and speculative stock, and if you've made a good profit on Rigetti, you may want to consider selling at least some of your shares.
Rocket Lab: $13,000
Another hot growth stock to own over the past year has been Rocket Lab. Although its 540% gain since last Halloween looks modest in comparison to Rigetti's, that would have still resulted in a $2,000 investment growing to a value of just under $13,000 today.
This aerospace company is also struggling with profitability, but it's generating far more revenue than Rigetti. Over the past four quarters, Rocket Lab has brought in $504.3 million in sales, although it incurred a net loss of $231.3 million in that period. It has a long way to go to reach breakeven, but investors are hoping that its Neutron rocket, which is larger than the Electron rocket it has been using thus far, could open up more lucrative and profitable opportunities for the business.
If the Neutron rocket has a successful initial launch later this year, this already hot stock could rise even higher. Rocket Lab is still a risky investment, but it may get to profitability a lot sooner than Rigetti.
Robinhood: $12,000
If you invested $2,000 into Robinhood at the end of October last year, your investment would now be worth a little less than $12,000, as it has risen by around 485%.
Robinhood's trading platform has evolved over the years, and now serves as a hub for people who want to buy and sell stocks or cryptocurrencies. The company has also expanded into "prediction markets," and a few months ago announced that it was launching prediction markets for the NFL and college football that will differ from standard sports betting.
Of these three companies, Robinhood is the only one that is profitable, and its margins aren't minimal, either. Over the past four quarters, the company has reported $1.8 billion in earnings on revenues of $3.6 billion. It trades at a price-to-earnings multiple of 74, which is undoubtedly high, but with its business expanding rapidly and with its brand remaining popular with retail investors, that premium may be justifiable.
Should you invest $1,000 in Rigetti Computing right now?
Before you buy stock in Rigetti Computing, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Rigetti Computing wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $590,357!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,141,748!*
Now, it’s worth noting Stock Advisor’s total average return is 1,033% — a market-crushing outperformance compared to 193% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
*Stock Advisor returns as of October 20, 2025
David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Rocket Lab. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

3 Scary-Good Growth Stocks That Would Have Turned $6,000 Invested Last Halloween Into $91,000 Today

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Moderna Inc (Symbol: MRNA), where a total of 91,472 contracts have traded so far, representing approximately 9.1 million underlying shares. That amounts to about 99.2% of MRNA's average daily trading volume over the past month of 9.2 million shares. Especially high volume was seen for the $27.50 strike call option expiring October 31, 2025, with 16,615 contracts trading so far today, representing approximately 1.7 million underlying shares of MRNA. Below is a chart showing MRNA's trailing twelve month trading history, with the $27.50 strike highlighted in orange:
MongoDB Inc (Symbol: MDB) options are showing a volume of 13,710 contracts thus far today. That number of contracts represents approximately 1.4 million underlying shares, working out to a sizeable 90.9% of MDB's average daily trading volume over the past month, of 1.5 million shares. Particularly high volume was seen for the $400 strike call option expiring November 21, 2025, with 3,398 contracts trading so far today, representing approximately 339,800 underlying shares of MDB. Below is a chart showing MDB's trailing twelve month trading history, with the $400 strike highlighted in orange:
And Rocket Lab Corp (Symbol: RKLB) saw options trading volume of 216,717 contracts, representing approximately 21.7 million underlying shares or approximately 84.3% of RKLB's average daily trading volume over the past month, of 25.7 million shares. Particularly high volume was seen for the $67 strike call option expiring October 24, 2025, with 15,715 contracts trading so far today, representing approximately 1.6 million underlying shares of RKLB. Below is a chart showing RKLB's trailing twelve month trading history, with the $67 strike highlighted in orange:
For the various different available expirations for MRNA options, MDB options, or RKLB options, visit StockOptionsChannel.com.
Also see:
FSIC shares outstanding history
BCYC YTD Return
CAPS Historical Stock Prices
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Notable Friday Option Activity: MRNA, MDB, RKLB

Motley Fool Co-Founder Tom Gardner: The Quarterly Call

Textron Inc. TXT is scheduled to release its third-quarter 2025 results on Oct. 23, before market open. The company delivered an earnings surprise of 6.9% in the last reported quarter.
Let’s discuss the factors that are likely to be reflected in the upcoming quarterly results.
Factors Likely to Affect TXT’s Q3 Results
Higher aircraft revenues, as well as aftermarket parts and services revenues, are likely to have boosted the Aviation unit’s revenues in the third quarter.
Higher military sales volumes, backed by the continued ramp-up of the Future Long Range Assault Aircraft program, along with increased commercial helicopter deliveries, are projected to have bolstered the Bell unit’s revenue performance.
Higher sales volumes from the Ship-to-Shore Connector program are likely to have bolstered TXT’s Industrial segment’s performance.
Lower sales volumes from the specialized vehicles are likely to have impacted TXT’s Industrial segment’s performance.
Textron Inc. Price and EPS Surprise
TXT’s Q3 Estimates
The robust revenue performance in three of its four major business segments is likely to have bolstered TXT’s overall top line.
The Zacks Consensus Estimate for TXT’s third-quarter revenues is pegged at $3.71 billion, which indicates growth of 8.1% from the year-ago quarter’s figure.
Solid sales growth expectations are likely to have contributed favorably to the company’s bottom line.
The Zacks Consensus Estimate for TXT’s earnings is pegged at $1.47 per share. This indicates a growth of 5% from the prior-year figure.
The consensus Estimate for TXT’s total backlog is pegged at $19.30 billion, which indicates growth of 20.7% from the year-ago quarter’s figure.
The Zacks Consensus Estimate for the Bell unit’s backlog is pinned at $8.90 billion, which indicates growth of 36.9% from the year-ago quarter’s figure.
What the Zacks Model Unveils
Our proven model does not conclusively predict an earnings beat for TXT this time. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is not the case here, as you will see below.
Earnings ESP: Textron has an Earnings ESP of -0.82%. You can uncover the best stocks before they’re reported with our Earnings ESP Filter.
Zacks Rank: TXT currently carries a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Stocks to Consider
Below, we have mentioned a few other players from the same sector that have the right combination of elements to beat on earnings in the upcoming releases:
CurtissWright CW is set to report third-quarter 2025 earnings on Nov. 5, 2025, after market close. It has an Earnings ESP of +1.59% and a Zacks Rank of 2 at present.
The Zacks Consensus Estimate for CW’s earnings is pegged at $3.28 per share, indicating year-over-year growth of 10.4%. The consensus estimate for its sales is pegged at $871.9 million, indicating year-over-year growth of 9.1%.
Rocket Lab RKLB is set to report its third-quarter 2025 earnings soon. It has an Earnings ESP of +25.00% and a Zacks Rank of 3 at present.
The Zacks Consensus Estimate for RKLB’s loss is pegged at five cents per share. The consensus estimate for its sales is pegged at $149.8 million, indicating year-over-year growth of 42.9%.
Woodward WWD is expected to report its fourth-quarter fiscal 2025 earnings soon. It has an Earnings ESP of +0.16% and a Zacks Rank of 3 at present.
The Zacks Consensus Estimate for WWD’s earnings is pegged at $1.83 per share, indicating year-over-year growth of 29.8. The consensus estimate for its sales is pegged at $935.8 million, indicating year-over-year growth of 9.5%.
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. Little-known AI firms tackling the world's biggest problems may be more lucrative in the coming months and years.
See "2nd Wave" AI stocks now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Textron to Post Q3 Earnings: Here's What's in the Cards

Key Points
The Ark Autonomous Technology & Robotics ETF is handily outpacing the "Magnificent Seven" stocks in 2025.
The Cathie Wood ETF owns 36 stocks, and some of its largest positions are smaller, up-and-coming companies.
This ETF can be a great way to get AI and technology exposure if you want to look beyond the mega caps.
The "Magnificent Seven" stocks have delivered a total return of approximately 18% through mid-October, based on the performance of the Roundhill Magnificent Seven ETF (NYSEMKT: MAGS). Although this isn't as impressive as the stellar 64% gain the collection of mega-cap tech stocks posted in 2024, it's still a strong performance over a period of less than a year.
However, this return pales in comparison to that of the Ark Autonomous Technology & Robotics ETF (NYSEMKT: ARKQ), an actively managed ETF led by notable tech investor Cathie Wood. The fund, which focuses on things like artificial intelligence, robotics, autonomous vehicles, and other major technology trends, has gained 56% so far in 2025.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
There's a solid case to be made that the ETF is still a smart buy for long-term investors right now. Here's why the Ark Autonomous Technology & Robotics ETF has performed so well, and why it could still be worth a look for investors who want an outside-the-box approach to AI and robotics investment.
A different approach to AI investing
The majority of ETFs that focus on AI and technology are heavily weighted toward mega-cap tech stocks like those in the Magnificent Seven. But not only is the Ark Autonomous Technology & Robotics ETF an actively managed ETF, but Cathie Wood and her team actively seek outside-the-box opportunities that many investors overlook.
To be fair, the fund's largest holding is Tesla (NASDAQ: TSLA), which is a Magnificent Seven stock. But beyond that, the rest of the top five is Kratos Defense & Security Solutions (NASDAQ: KTOS), Teradyne (NASDAQ: TER), Rocket Lab USA (NASDAQ: RKLB), and Archer Aviation (NYSE: ACHR). Some of the other Magnificent Seven components are owned by the fund but aren't among the largest investments -- for example, Amazon.com (NASDAQ: AMZN) and Nvidia (NASDAQ: NVDA) are the fund's No. 13 and No. 15 stocks, respectively, in a portfolio of only 36 companies.
Why has the Ark Autonomous Technology & Robotics ETF beaten the ETF tracking the Magnificent Seven?
The short explanation is that some of the fund's largest holdings have delivered excellent returns so far in 2025. Kratos and Rocket Lab are up by 239% and 162%, respectively, for the year as of this writing. Palantir (NASDAQ: PLTR), the ETF's sixth-largest investment, is higher by 134%.
I could go on, but you get the idea. Not all of the stocks in the Ark Autonomous Technology & Robotics ETF have delivered market-beating performance this year, but a good number of the fund's stocks are up by triple digits.
To be thorough, the Ark Autonomous Technology & Robotics ETF has a 0.75% expense ratio, which is certainly higher than you'll find from many index ETFs. This means that for every $1,000 in assets, you're paying the fund managers $7.50 per year. However, it is on par with what other AI-focused ETFs charge, and the recent performance speaks for itself. Note: This isn't a fee you pay -- it will simply be reflected in the ETF's performance over time.
An ETF worth looking into
If you're looking for a way to get exposure to artificial intelligence as well as some other exciting tech trends in the market, but you don't necessarily want to invest in the mega caps, the Ark Autonomous Technology & Robotics ETF could be worth a look. It is full of high-potential companies and although it has outperformed this year, there's a lot of upside potential if its major holdings can execute on their respective growth strategies.
Should you invest $1,000 in Ark ETF Trust - Ark Autonomous Technology & Robotics ETF right now?
Before you buy stock in Ark ETF Trust - Ark Autonomous Technology & Robotics ETF, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Ark ETF Trust - Ark Autonomous Technology & Robotics ETF wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $667,945!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,119,558!*
Now, it’s worth noting Stock Advisor’s total average return is 1,073% — a market-crushing outperformance compared to 191% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
*Stock Advisor returns as of October 20, 2025
Matt Frankel has positions in Amazon. The Motley Fool has positions in and recommends Amazon, Nvidia, Palantir Technologies, Rocket Lab, and Tesla. The Motley Fool recommends Teradyne. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This ETF Is Outpacing the Entire "Magnificent Seven" in 2025. Is It Still a Buy?

Below is Validea's guru fundamental report for ROCKET LAB CORP (RKLB). Of the 22 guru strategies we follow, RKLB rates highest using our Small-Cap Growth Investor model based on the published strategy of Motley Fool. This strategy looks for small cap growth stocks with solid fundamentals and strong price performance.
ROCKET LAB CORP (RKLB) is a large-cap growth stock in the Aerospace & Defense industry. The rating using this strategy is 48% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
Detailed Analysis of ROCKET LAB CORP
More Information on Motley Fool
About Motley Fool: Brothers David and Tom Gardner often wear funny hats in public appearances, but they're hardly fools -- at least not the kind whose advice you should readily dismiss. The Gardners are the founders of the popular Motley Fool web site, which offers frank and often irreverent commentary on investing, the stock market, and personal finance. The Gardners' "Fool" really is a multi-media endeavor, offering not only its web content but also several books written by the brothers, a weekly syndicated newspaper column, and subscription newsletter services.
Additional Research Links
Top Russell 2000 Stocks
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

RKLB Quantitative Stock Analysis

Guru Fundamental Report for RKLB

Key Points
The launch of a brand new rocket later this year could put Rocket Lab shares into orbit.
Demand for Navitas Semiconductor’s superior solution is likely to soar from here, in light of its partnership with a high-profile AI outfit.
Recursion Pharmaceuticals won’t be profitable for a while longer, but the potential of its platform may be bullish enough by itself between now and then.
It's tough to get excited about buying most growth stocks right now. Too many of them are just too expensive relative to the risk they bring to the table.
Not all of them, though. If you're willing to look a bit off the beaten path, you'll find some compelling prospects. If you've got an extra $1,000 available that you're ready to put to work and can stomach above-average volatility, here's a closer look at three such names.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
Rocket Lab
Putting satellites -- and even people -- into Earth's orbit is no longer strictly government work. The industry is being democratized by virtue of being privatized. Elon Musk's SpaceX is one of the better-known names in the business. SpaceX isn't the only name in the nascent business, however, nor is it publicly traded. A smaller outfit called Rocket Lab (NASDAQ: RKLB) offers a top way for investors to capitalize on the rapid proliferation of what was barely even an idea just a few years ago.
It's called the Electron. The 60-foot rocket capable of lifting up to 661 pounds worth of equipment is one of the world's first and only reusable launch systems. To date, 73 launches of the Electron have put a total of 239 satellites into orbit. The company seems to have mastered the art and science of this sliver of the space launch business, refining the Electron with each and every flight.
It's not the chief reason you might want to step into a stake in this company sooner than later, though. There's some urgency here because Rocket Lab will very likely be launching a much bigger rocket soon. Specifically, its new Neutron rocket, capable of putting over 14 tons' worth of equipment (or personnel) into orbit, is expected to make its first-ever flight sometime before the end of this year.
This will only be a test flight. But the company's success with its Electron design bodes well for Rocket Labs' plans for a couple more launches of Neutron next year, with a handful more launches of the bigger rocket slated for 2027. Each successful flight will make the company more of a competitor to SpaceX within the all-important medium-lift sliver of the space launch market that Global Market Insights believes is set to grow at an average annual pace of nearly 15% through 2034.
Rocket Lab also provides a wide range of technological solutions for satellites, landers, and ground control, rounding out its revenue quite nicely.
Navitas Semiconductor
There was a time when one semiconductor manufacturer was just as good an investment as another. Not anymore, though. The advent of mobile devices, cloud computing, and artificial intelligence has created the need for advanced, specialized solutions.
Enter Navitas Semiconductor (NASDAQ: NVTS).
It's not a major player in the business like Nvidia or Intel, at least not yet. In fact, this $3 billion outfit only did $83 million worth of business last year.
What Navitas lacks in size, however, it more than makes up for in potential.
The key is the material that the company uses in its chips. Gallium nitride can handle more electricity than the simple silicon-based components you'll find in most modern-day electronics, allowing for smaller as well as more power-efficient devices. The science has potential for use in lower-voltage tech ranging from mobile phones to imaging equipment to automobiles to computers. The company's also working with silicon carbide, however, which offers similar advantages over basic silicon, but is better-suited and more affordable for higher voltage applications like electric vehicles and power-hungry data centers.
The two materials can be used somewhat interchangeably, although each one's unique pros and cons will likely mean both have their place in the foreseeable future. Navitas Semiconductor is readying itself for whatever awaits. Other companies are working with these same materials, by the way. But, few seem as developmentally far along as this one.
The chief challenge here is just that this promising future isn't yet the present. While most of the technology sector understands that it must begin offering more power-efficient solutions, shifting away from basic silicon that's proven itself for decades now is easier said than done.
That finally seems to be officially changing, though. On Monday, Navitas unveiled a new gallium nitride-based switch purpose-built specifically for AI-market-leading Nvidia's 800-volt artificial intelligence data center architecture. This high-profile partnership could all but force this tech to become the new industry standard.
That being said, you might want to wait a few days before diving in. Shares soared on the heels of the Nvidia news, and might be due for a slight pullback in the near future. That would be a better buying opportunity. Just be smart.
Recursion Pharmaceuticals
Finally, add Recursion Pharmaceuticals (NASDAQ: RXRX) to your list of growth stocks to invest in right now if you've got $1,000 you're ready to put to work and don't mind taking a little risk.
The idea of artificial intelligence-created pharmaceuticals is still just that -- an idea. It would likely take a sort of generative AI platform that's yet to be invented to figure out how to make something out of nothing, starting with nothing more than a goal.
There is a stepping stone en route to that eventual possibility, however. If you can program enough of the right chemical and biological parameters into a platform, it's possible to determine how a particular drug might perform as a therapy, or figure out how a particular molecule can be created in the first place. That's what Recursion Pharmaceuticals' RecursionOS does. Leveraging 65 petabytes' (65 million gigabytes) worth of scientific data, drug developers can complete a simulated test of an idea in a matter of days that might otherwise take months if not years in a laboratory or clinical setting.
It's not a substitute for an actual clinical trial, to be clear. The FDA and other nations' regulatory agencies will still require real-world trials to approve any new drug. The technology still offers something enormously important to pharmaceutical companies, though. That is, it lets drug developers know what's worth pursuing and what isn't. And when the average cost of bringing a new drug to the market can easily cost over $1 billion -- and when nine out of 10 drugs that begin clinical trials fail rather than ending in an approval -- that's huge, by virtue of helping pharma companies to focus their resources on the most promising of prospects.
There are two ways to monetize RecursionOS. One of them is the development of Recursion's own drugs. The other is by providing the platform to conventional developers like Sanofi and Roche, both of which are currently utilizing the AI-powered platform to create new therapies. All told, Recursion Pharmaceuticals' platform launched seven different clinical trials now underway.
This is still just the beginning, though. Straits Research expects the artificial intelligence-driven drug discovery market to grow at an average annualized pace of 32% through 2030. That may not be enough to drag Recursion out of the red and into the black, but it will certainly move the needle in that direction. This prospect may be enough to push the stock upward in the meantime.
Don’t miss this second chance at a potentially lucrative opportunity
Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.
On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:
Nvidia: if you invested $1,000 when we doubled down in 2009, you’d have $475,196!*
Apple: if you invested $1,000 when we doubled down in 2008, you’d have $47,949!*
Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $646,805!*
Right now, we’re issuing “Double Down” alerts for three incredible companies, available when you join Stock Advisor, and there may not be another chance like this anytime soon.
*Stock Advisor returns as of October 13, 2025
James Brumley has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Intel, Nvidia, and Rocket Lab. The Motley Fool recommends Roche Holding AG and recommends the following options: short November 2025 $21 puts on Intel. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

3 Growth Stocks to Invest $1,000 in Right Now

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the First Trust Large Cap Growth AlphaDEX Fund (Symbol: FTC) where we have detected an approximate $311.7 million dollar outflow -- that's a 19.8% decrease week over week (from 9,850,002 to 7,900,002). Among the largest underlying components of FTC, in trading today Rocket Lab Corp (Symbol: RKLB) is up about 0.1%, Vertiv Holdings Co (Symbol: VRT) is down about 1.6%, and Newmont Corp (Symbol: NEM) is lower by about 6.2%. For a complete list of holdings, visit the FTC Holdings page » The chart below shows the one year price performance of FTC, versus its 200 day moving average:
Looking at the chart above, FTC's low point in its 52 week range is $113.13 per share, with $163.35 as the 52 week high point — that compares with a last trade of $159.81. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Also see:
Funds Holding ADSW
ZNDX Options Chain
CHEB YTD Return
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Indicator	TTM Median
P/E	0.00 21.58
Price/Sales	22.21 1.29
P/B	15.99 2.25
P/FCF	0.00 17.83

Indicator	TTM Median
ROE	-34.12 15.71
ROA	-16.61 6.45
Net Worth	7.25 1.27
Quick Ratio	2.43 1.16
Current Ratio	2.58 1.57

Indicator	TTM Median
Net Profit Margin	-54.13 7.31
Operating Margin	-51.10 10.18
Gross Margin	24.77 32.50
Return on tangible equity	-55.17 25.81

Indicator	TTM Median
EPS	0.10 0.49
EPS Forecast	0.11 0.53
Revenue	106.00M 194.00M
Gross Profit	27.00M —
EBITDA	-43.00M —

Rocket Lab Corporation

TTM metrics for the latest quarter under IFRS and their historical dynamics

Valuation

Debts

Efficiency

Other ratios

Revenue